-
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· New York: Maspeth, New York
-
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606 ·
Phase: Phase 3 ·
Ages: 2 Years to 19 Years ·
Sex: All (male and female)
· New York: New York
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT07113522 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: New York, Rochester
-
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Carmel, New York
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Carmel, New York
-
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
NCT06581328 ·
Phase: Phase 4 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: Carmel, Cedarhurst, Elmhurst, Fresh Meadows
-
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· New York: New Hyde Park, Rochester, Stony Brook
-
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New Hyde Park, Rochester, Stony Brook, Syracuse
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York, Rochester
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· New York: Brooklyn, Fresh Meadows, The Bronx, Utica
-
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· New York: New York, North Massapequa, Queens Village, Richmond Hill
-
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
NCT07298421 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· New York: Great Neck, Middletown, New York, Port Jefferson
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Queens Village
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· New York: Maspeth, New York
-
Autologous Stem Cell Transplant for Crohn's Disease
NCT03219359 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Behavioral Therapy for Crohn's Disease
NCT06512597 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
NCT05781152 ·
Phase: Phase 4 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Lake Success, New York
-
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281 ·
Phase: Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· New York: New York
-
Helmsley 3.0: Abbreviated MRE
NCT06533228 ·
Phase: Not specified ·
Ages: 10 Years and older ·
Sex: All (male and female)
· New York: New York
-
Low Dose IL-2 for the Treatment of Crohn's Disease
NCT04263831 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: New York, Yonkers
-
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
NCT06864403 ·
Phase: Phase 4 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
NCT06976853 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
NCT06001450 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Standardized Microbiota Transplant Therapy in Crohn's Disease
NCT06631586 ·
Phase: Phase 2 ·
Ages: 18 Years to 89 Years ·
Sex: All (male and female)
· New York: New York
-
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Lake Success, New York, Yonkers
-
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
NCT03256240 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· New York: New York
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Mineola, New York
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
NCT06274554 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Burnt Hills, New York, Rochester
-
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
NCT07237516 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York